Premium
EARLY SAFETY AND EFFICACY DATA FROM A PHASE I/II TRIAL OF DZD4205, A SELECTIVE JAK1 INHIBITOR, IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA
Author(s) -
Kim W.S.,
Yoon D.H.,
Song Y.,
Koh Y.,
Cao J.,
Ji D.,
Yang H.,
Eom H.S.,
Jing H.,
Kwak J.Y.,
Lee W.S.,
Lee J.S.,
Shin H.J.,
Jin J.,
Wang M.,
Li J.,
Huang X.,
Deng X.,
Yang Z.,
Zhu J.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.57_2879
Subject(s) - medicine , tolerability , peripheral t cell lymphoma , refractory (planetary science) , lymphoma , clinical trial , phases of clinical research , transplantation , oncology , gastroenterology , adverse effect , surgery , t cell , immunology , immune system , physics , astrobiology